23hon MSN
Research links weight loss medications like Ozempic and Zepbound to certain serious eye conditions.
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
Gastrointestinal adverse events partially mediated the weight loss effects among patients with obesity who received tirzepatide vs placebo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback